Baseline Characteristics for Esophageal Cancer Patients on Adjuvant Nivolumab

151 patients from three Dutch hospitals who received adjuvant nivolumab after surgery for esophageal or gastroesophageal junction cancer between September 2021 and October 2023. The dataset includes patient characteristics, treatment details, and imaging intervals, with primary outcomes of disease recurrence and disease-free survival. Disease-free survival was 89% at 4 months, declining to 75% at 12 months.

Use Cases

• Analyze recurrence detection rates based on routine CT imaging intervals mentioned in the description
• Model disease-free survival over time based on the reported 4, 8, and 12-month statistics
• Compare diagnostic yield of CT scans at baseline versus during treatment based on the reported 0% and 9% figures

Strengths

• Includes data from 151 patients across three hospitals, providing a multi-center perspective.
• Reports specific clinical outcomes, including disease-free survival rates at 4, 8, and 12 months (89%, 84%, 75%).
• Captures real-world data on a specific treatment regimen (adjuvant nivolumab) within a defined 2021-2023 timeframe.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 5.5 KB, indicating limited scope.

Provenance

Source

figshare, author Tamara J. Huizer.

Collection Method

Multi-center, retrospective cohort study collecting data from three hospitals in the Netherlands.

Time Range

Surgical resections performed between September 2021 and October 2023.

Freshness

Last updated 2026-06-02 17:24:55; freshness should be verified.

Geography

Patients from three hospitals in the Netherlands.